
## Victor Garcia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3281268/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Sequencing of 640,000 exomes identifies <i>GPR75</i> variants associated with protection from obesity. Science, 2021, 373, .	6.0	130
2	20-HETE Signals Through G-Protein–Coupled Receptor GPR75 (G <sub>q</sub> ) to Affect Vascular Function and Trigger Hypertension. Circulation Research, 2017, 120, 1776-1788.	2.0	119
3	20-HETE and Blood Pressure Regulation. Cardiology in Review, 2014, 22, 1-12.	0.6	117
4	Endothelial NOS: perspective and recent developments. British Journal of Pharmacology, 2019, 176, 189-196.	2.7	110
5	Vascular actions of 20-HETE. Prostaglandins and Other Lipid Mediators, 2015, 120, 9-16.	1.0	107
6	Induction of Angiotensin-Converting Enzyme and Activation of the Renin–Angiotensin System Contribute to 20-Hydroxyeicosatetraenoic Acid–Mediated Endothelial Dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1917-1924.	1.1	57
7	Androgen-Sensitive Hypertension Associates with Upregulated Vascular CYP4A12–20-HETE Synthase. Journal of the American Society of Nephrology: JASN, 2013, 24, 1288-1296.	3.0	52
8	Hypertension Is a Major Contributor to 20-Hydroxyeicosatetraenoic Acid–Mediated Kidney Injury in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 597-610.	3.0	44
9	20-HETE Activates the Transcription of Angiotensin-Converting Enzyme via Nuclear Factor-ÂB Translocation and Promoter Binding. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 525-533.	1.3	41
10	Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. FASEB Journal, 2014, 28, 2915-2931.	0.2	33
11	Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R71-R78.	0.9	29
12	High-fat diet-induced obesity and insulin resistance in CYP4a14 <sup>â^`/â^`</sup> mice is mediated by 20-HETE. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2018, 315, R934-R944.	0.9	29
13	20-HETE induces remodeling of renal resistance arteries independent of blood pressure elevation in hypertension. American Journal of Physiology - Renal Physiology, 2013, 305, F753-F763.	1.3	27
14	Androgen-sensitive hypertension associated with soluble guanylate cyclase-α <sub>1</sub> deficiency is mediated by 20-HETE. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H1790-H1800.	1.5	27
15	20-HETE interferes with insulin signaling and contributes to obesity-driven insulin resistance. Prostaglandins and Other Lipid Mediators, 2021, 152, 106485.	1.0	22
16	Androgen-induced hypertension in angiotensinogen deficient mice: Role of 20-HETE and EETS. Prostaglandins and Other Lipid Mediators, 2015, 116-117, 124-130.	1.0	21
17	Uncovering the signalling, structure and function of the 20â€HETEâ€GPR75 pairing: Identifying the chemokine CCL5 as a negative regulator of GPR75. British Journal of Pharmacology, 2021, 178, 3813-3828.	2.7	21
18	CYP4A/20-HETE regulates ischemia-induced neovascularization via its actions on endothelial progenitor and preexisting endothelial cells. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1468-H1479.	1.5	19

VICTOR GARCIA

#	Article	IF	CITATIONS
19	Recent developments on the vascular effects of 20-hydroxyeicosatetraenoic acid. Current Opinion in Nephrology and Hypertension, 2016, 26, 1.	1.0	18
20	Unbiased proteomics identifies plasminogen activator inhibitor-1 as a negative regulator of endothelial nitric oxide synthase. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9497-9507.	3.3	16
21	Heme-oxygenase and lipid mediators in obesity and associated cardiometabolic diseases: Therapeutic implications. , 2021, , 107975.		16
22	GATA6 reporter gene reveals myocardial phenotypic heterogeneity that is related to variations in gap junction coupling. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H1952-H1964.	1.5	13
23	Unraveling the Role of 12- and 20- HETE in Cardiac Pathophysiology: G-Protein–Coupled Receptors, Pharmacological Inhibitors, and Transgenic Approaches. Journal of Cardiovascular Pharmacology, 2021, 77, 707-717.	0.8	13
24	The Blood Pressure–Lowering Effect of 20-HETE Blockade in <i>Cyp4a14(â^'/â^')</i> Mice Is Associated with Natriuresis. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 412-418.	1.3	11
25	19-Hydroxyeicosatetraenoic acid analogs: Antagonism of 20-hydroxyeicosatetraenoic acid-induced vascular sensitization and hypertension. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126616.	1.0	9
26	Blockade of 20-hydroxyeicosatetraenoic acid receptor lowers blood pressure and alters vascular function in mice with smooth muscle-specific overexpression of CYP4A12-20-HETE synthase. Journal of Hypertension, 2022, 40, 498-511.	0.3	8
27	The CYP/20-HETE/GPR75 axis in hypertension. Advances in Pharmacology, 2022, , 1-25.	1.2	6
28	Proximal tubule-targeted overexpression of the Cyp4a12-20-HETE synthase promotes salt-sensitive hypertension in male mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2020, 319, R87-R95.	0.9	4
29	20â€ <del>S</del> OLA, a Novel Water Soluble 20â€HETE Antagonist, Reduces Blood Pressure Through Regulation of Vascular ACE Expression via an IKK Dependent Pathway. FASEB Journal, 2015, 29, 647.9.	0.2	1
30	Androgen-sensitive hypertension associated with soluble guanylate cyclase alpha1 deficiency is mediated by 20-HETE. BMC Pharmacology & Toxicology, 2015, 16, .	1.0	0
31	20â€HETE INDUCES REMODELING OF RENAL RESISTANCE ARTERIES INDEPENDENT OF BLOOD PRESSURE ELEVATION IN ANDROGENâ€INDUCED HYPERTENSION. FASEB Journal, 2013, 27, 685.10.	0.2	0
32	Vascular Endothelial ACE Deletion does not Prevent 20â€HETEâ€dependent Vascular Remodeling. FASEB Journal, 2015, 29, 630.4.	0.2	0
33	Deletion of the 20â€HETE receptor (GPR75) impairs myogenic tone of renal preglomerular arteries. FASEB Journal, 2019, 33, 692.9.	0.2	0
34	Identifying the 20â€HETE Binding Site on the 20â€HETE Receptor (GPR75). FASEB Journal, 2020, 34, 1-1.	0.2	0
35	Pharmacological blockade of the 20â€HETE receptor (GPR75) lowers blood pressure and alters vascular remodeling in mice with vascular smooth muscleâ€specific overexpression of CYPâ€4a12â€20â€HETE synthase. FASEB Journal, 2020, 34, 1-1.	0.2	0
36	Structureâ€Function Relationship of the 20â€HETEâ€GPR75 pairing: Development and characterization of agonist, partial agonists, and receptor blockers. FASEB Journal, 2022, 36, .	0.2	0